Summary
Unable to evaluate most claims because the provided FDA label excerpts cover only contraindications/warnings related to infections, TB screening, and immunizations. No label excerpts were provided for the product’s approved indications, dosage/administration details (including subcutaneous injection), or dosing by condition/age.
Category Scores
Accurate Statements
Unsupported Statements
Taltz (ixekizumab) is used to treat plaque psoriasis (including moderate-to-severe disease).
No FDA label excerpt provided for approved indications.
Taltz (ixekizumab) is used to treat psoriatic arthritis.
No FDA label excerpt provided for approved indications.
Taltz (ixekizumab) is used to treat ankylosing spondylitis.
No FDA label excerpt provided for approved indications.
Taltz (ixekizumab) is used to treat non-radiographic axial spondyloarthritis.
No FDA label excerpt provided for approved indications.
Taltz is prescribed when the conditions it treats require systemic (whole-body) therapy rather than only topical treatment.
No FDA label excerpt provided describing selection criteria such as systemic vs topical therapy.
Taltz is administered by injection via the subcutaneous route.
No FDA label excerpt provided for dosage form/route of administration.
Taltz dosing depends on the specific condition being treated and the patient’s age.
No FDA label excerpt provided for dosing regimen by condition and/or age.
For psoriatic arthritis, Taltz is used to help control joint inflammation and symptoms.
No FDA label excerpt provided for indication-specific description of effects.
For axial spondyloarthritis conditions, Taltz is used to reduce inflammation in the spine and related areas, including symptoms like pain and stiffness.
No FDA label excerpt provided for indication-specific description of effects or symptoms.
Contradictions
Important Omissions
The provided audit did not include FDA label text for approved indications, dosage and administration (including dose amounts, titration, dosing intervals), and route/administration instructions. These are required to verify the listed indication and dosing/administration claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
Because the evaluation cannot verify indications, dosing, and route details against the provided label excerpts, potential risk from possible inaccuracies cannot be determined from the supplied information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable
Primary Issue
Insufficient FDA label excerpts to verify the majority of claims (indications, dosing/age dependence, and subcutaneous administration).
Suggested Improvement
Provide the exact FDA label sections for Indications and Usage, Dosage and Administration (including route and dosing schedules), and any label text describing systemic therapy vs topical therapy criteria; then re-evaluate each claim against those sections.